5
Primary Results: The Standard Care versus COrticosteroid for REtinal Vein Occlusion Study (The SCORE Study) SCORE Study Research Group Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health and Human Services (Funded by NEI 2003)

11
Both triamcinolone groups were superior to the observation group for VA at 12 months Visual benefit as early as 4 months Visual benefit continued to 24 months The 1-mg dose has a safety profile superior to that of the 4-mg dose and similar to observation SCORE CRVO Conclusion CRVO Trial

17
Ozurdex Trials Conclusions DEX groups’ time to gain 15 letters was significantly shorter than sham eyes through day 90 Mean change in BCVA was statistically: – Better for DEX groups for BRVO through day 180 – Better for DEX groups for CRVO through day 90 Persistence of efficacy in 21% BRVO; 17% CRVO at month 12 required only 1 Rx